Aslan, ACT Genomics deal

Aslan and ACT partnered to research the genomic background of patients who displayed better than expected response rates in a clinical trial of ASLAN001, an oral small molecule inhibitor of EGFR and EGFR2 ( HER2; ErbB2; neu). The compound is in clinical testing to treat breast cancer, gastric cancer and cholangiocarcinoma. Data from a Phase II trial in breast cancer are expected by year end, and data from other indications are expected next year. ...